Precision medicine treatments for Parkinson’s Disease closer to reality thanks to Sheffield study
- A new study from the University of Sheffield paves the way for the development of ‘precision medicine’ approaches for the treatment of Parkinson’s Disease
- The study identified two separate patient groups with different impaired cell mechanisms causing the development of the disease
- The findings will help scientists develop effective treatments tailored to specific causes of the disease for the first time
- 145,000 people in the UK are living with Parkinson’s Disease and it is estimated 1 in 37 of us will develop it in our lifetimes
- The University has launched a fundraising appeal to advance research into Parkinson's Disease
A huge step forward has been made in understanding the multiple ways Parkinson’s Disease can develop; the findings of which could be a crucial catalyst to discover new personalised drug treatments.
A new study from the University of Sheffield, published in Progress in Neurobiology, has identified two different abnormal mechanisms that underpinned the development of the disease in two different groups of patients with the common sporadic form of Parkinson’s Disease.
The study was carried out in collaboration with the University of Oxford and is the largest study to date to use patient tissue from skin biopsy samples from people living with Parkinson’s Disease.
Some of these samples were transformed in the laboratory into the type of nerve cells found in the brain that are affected by the progressive brain disease.
The two groups displayed either mitochondrial or lysosomal dysfunction. This dysfunction impairs the cell’s batteries (the mitochondria) or the cell’s waste system (the lysosomes).
Both mitochondrial and lysosomal dysfunction are important causes of nerve cell death in Parkinson’s Disease and are likely to contribute to the progression of the main symptoms including; loss of movement, tremors and rigidity.
Crucially, the study found that the abnormal mechanisms were still present in the transformed nerve cells, so promising neuroprotective compounds, or brain rescue drugs could be tested directly in patient tissue.
Professor Oliver Bandmann, from the University of Sheffield’s Institute for Translational Neuroscience (SITraN), said: “As the underlying reasons for developing Parkinson’s Disease are different in each person, to develop treatments that stop the disease from progressing we need to find out exactly how and why each person develops the disease, which can be very different.
“The findings of our study are very exciting. They provide evidence that using a mechanistic stratification to look at the specific factors causing the development of the disease can identify new targets to help scientists develop precision medicine approaches for groups of patients that have similar impaired cell mechanisms.”
Other SITraN-based scientists contributing to the study include Dr Heather Mortiboys, Dr Laura Ferraiuolo and Professor Winston Hide, now based at Harvard Medical School.
Professor Bandmann is also already leading a clinical trial, the UP study, to find out whether ursodeoxycholic acid (UDCA) may slow down disease progression in Parkinson’s Disease. UDCA was the lead compound of a drug screen study previously carried out at SITraN.
Professor Bandmann added: “There currently isn’t a treatment available we can give people living with Parkinson’s Disease that can slow down or stop its progression.
“The results of this study will help scientists to understand how to develop new personalised drug therapies for neurodegenerative diseases and develop effective drugs to rescue the function of the cells affected and help the brain recover for the first time.”
The research forms part of the work of the University of Sheffield’s Neuroscience Institute, which aims to bring academics and scientists together from across varied specialties to translate scientific discoveries from the lab into pioneering treatments that will benefit patients living with neurodegenerative disorders.
The University of Sheffield has launched a fundraising appeal to help support its research into Parkinson's Disease, for more information see here: sheffield.ac.uk/causes/parkinsons
- The study was funded by Parkinson’s UK with additional support from the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC).
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For more information, please contact:
Media Relations Officer
0114 222 9859